Status:
COMPLETED
PET Imaging of the Immune System Using Analog Probes
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborating Sponsors:
Tesaro, Inc.
GlaxoSmithKline
Conditions:
Malignant Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this proposal is to assess the biodistribution of 18F-Clofarabine, a new tracer developed for use in PET/CT scans. The investigator's hypothesis is this tracer will allow for imaging immun...
Detailed Description
This is a non-interventional pilot study dedicated to PET imaging for patients with metastatic or recurrent advanced cancer melanoma before and after immune therapy interventions with an anti-TIM-3 mo...
Eligibility Criteria
Inclusion
- The following inclusion criteria also apply:
- Subject must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)
- Subject must be 18 years or older
- Participation in a main study of anti-TIM-3
Exclusion
- Patients who meet the exclusion criteria are excluded from this study. 1. Pregnancy
- Women of childbearing potential will have to undergo a pregnancy test that will be provided free of charge.
- Current knowledge indicates no confirmed detrimental effects to a developing fetus of radiation doses below 10,000 mrem. The radiation dose received from the study procedure is very small in comparison, however, the exclusion criteria is in place to minimize any potential for exposure of a fetus.
Key Trial Info
Start Date :
April 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 10 2020
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03409419
Start Date
April 10 2018
End Date
November 10 2020
Last Update
October 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095